Aspirin increases breast cancer survival over 67%
BMJ trashes most Chemotherapies
Cancer screening doesn't save lives
Aspirin increases breast cancer survival over 67%
Aspirin for treating adenocarcinoma and other cancers
Cancer Drugs that Failed NICE Reviewed, but are frequently used in UK
Avastin cancer drug avoid

Aspirin 325 mgs daily increases breast cancer survival for stage I, II, III by an average of 67% (see note below). Aspirin reduces the risk of most major cancers, thus it is reasonable to presume that for most major cancers a similar benefit would be observed--if PhARMA decided to fund such work.  Aspirin stimulates the body’s mechanism for the destruction of abnormal cells (including some types of cancer, most adenocarcinomas).  It works for stage I, II, and III, before the cancer has developed the ability to fool the immune system into permitting metastases.

10.1200/JCO.2009.22.7918 JCO March 20, 2010 vol. 28 no. 9 1467-1472

Aspirin Intake and Survival After Breast Cancer

+ Author Affiliations

  1. From the Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA.
  1. Corresponding author: Michelle D. Holmes, MD, DrPH, Channing Laboratory, 181 Longwood Ave, Boston, MA 02115; e-mail:


Purpose Animal and in vitro studies suggest that aspirin may inhibit breast cancer metastasis. We studied whether aspirin use among women with breast cancer decreased their risk of death from breast cancer.

Methods This was a prospective observational study based on responses from 4,164 female registered nurses in the Nurses' Health Study who were diagnosed with stages I, II, or III breast cancer between 1976 and 2002 and were observed until death or June 2006, whichever came first. The main outcome was breast cancer mortality risk according to number of days per week of aspirin use (0, 1, 2 to 5, or 6 to 7 days) first assessed at least 12 months after diagnosis and updated.

Results There were 341 breast cancer deaths. Aspirin use was associated with a decreased risk of breast cancer death. The adjusted relative risks (RRs) for 1, 2 to 5, and 6 to 7 days of aspirin use per week compared with no use were 1.07 (95% CI, 0.70 to 1.63), 0.29 (95% CI, 0.16 to 0.52), and 0.36 (95% CI, 0.24 to 0.54), respectively (test for linear trend, P < .001). This association did not differ appreciably by stage, menopausal status, body mass index, or estrogen receptor status. Results were similar for distant recurrence. The adjusted RRs were 0.91 (95% CI, 0.62 to 1.33), 0.40 (95% CI, 0.24 to 0.65), and 0.57 (95% CI, 0.39 to 0.82; test for trend, P = .03) for 1, 2 to 5, and 6 to 7 days of aspirin use, respectively.

Conclusion Among women living at least 1 year after a breast cancer diagnosis, aspirin use was associated with a decreased risk of distant recurrence and breast cancer death.

NOTE:  increased survival of 71%  (29 – 100 = 71%) for 2-5 days per week; and for 6-7 days per week of 64% (100-36 = 64%).  The 1.07 are for those who take an average of 1 per week.  Thus compared to the 4,164 recorded breast cancers, those who took no aspirin or 1 aspirin/week had worse than average results of the general population which included both aspirin takes and non-users.  Thus averaging the 2 groups of aspirin users, the survival rate is 67.5% higher.   During the period when the study started the higher dose 325 mg and 500 mg were on the market, the lower dose 82 mgs, wasn’t widely used until the statins became a market force.  

Enter supporting content here